As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

Cambridge Isotope Laboratories, Inc. Announces the First Commercially Available Quantum-Grade Gas, 12C Methane QG-alpha™, for High-Performance Nitrogen-Vacancy (NV) Center Diamonds 

July 7, 2021
Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, is proud to launch the first commercially available 12C-enriched methane-grade gas for quantum applications. 
“Quantum magnetometers and quantum key distribution (QKD) often rely on nitrogen-vacancy center diamonds, also known as NV centers or color centers diamonds,” states CIL’s Director of European Business Development, Joel Louette. “Regardless of which method is used to synthetize these NV centers diamonds, chemical vapor deposition (CVD) or high-pressure high-temperature (HPHT), they require an ultrahigh-purity starting material, highly enriched in 12C and very low nitrogen content. The low nitrogen content facilitates the implementation of the exact number of NV centers in the diamond, while the high 12C enrichment dramatically increases the coherence time at room temperature.” 
For decades, CIL has worked with the best academic laboratories and diamond industry leaders to provide a starting material compatible for their applications. CIL’s 12C methane QG-alpha material offers 99.99% (4N) 12C enrichment and 3 ppm or less of nitrogen content.
To learn more about CIL’s quantum-grade 12C methane gas visit
About Cambridge Isotope Laboratories, Inc.   
CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.   
For more information on CIL, visit   
Back to list
CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.